Bioinspired Nanoarchitectures Dramatically Enhance Oral Bioavailability and Sustained Release of Insulin and GLP-1 Analogs
Background
Management of diabetes mellitus heavily relies on peptide therapeutics such as insulin and glucagon-like peptide-1 (GLP-1) analogues. However, their clinical utility is severely hampered by rapid enzymatic degradation within the gastrointestinal tract, poor epithelial permeability limiting oral absorption, and short systemic half-lives necessitating frequent injections. These limitations lead to suboptimal patient adherence and fluctuating therapeutic levels. Addressing these gaps requires innovative delivery strategies that can protect peptides, facilitate their absorption, and control their release kinetics, thereby improving efficacy and patient quality of life.
Study Design
This comprehensive review synthesized and evaluated recent advances in bioinspired nanoarchitectures designed to overcome the delivery challenges of antidiabetic peptides. Researchers systematically assessed various strategies, including membrane-mimetic lipid nanocarriers, polymer-based systems, peptide-driven self-assembling depots, and stimuli-responsive nanoarchitectures. The review focused on their application with therapeutics like insulin analogues and GLP-1 receptor agonists, covering advanced formulations such as hydrophobic ion-paired exenatide lipid nanocarriers, charge-switchable PCB122/INS nanoparticles, polymeric D-PLA-PEG stereocomplex nanoassemblies, and glucose oxidase-integrated hydrogels.
Results
The review highlighted significant improvements in peptide delivery using bioinspired nanoarchitectures. Lipid-inspired systems, specifically hydrophobic ion-paired exenatide lipid nanocarriers, achieved oral bioavailability ranging from 16.3% to 27.9%. Polymer-based systems, such as charge-switchable PCB122/INS nanoparticles within coated capsules, enabled oral insulin bioavailability approaching ~27%, leading to sustained glucose lowering effects in vivo. > A polymeric D-PLA-PEG stereocomplex nanoassembly demonstrated ultra-long insulin release for up to 16 weeks following a single subcutaneous administration, maintaining controlled blood glucose levels in type 1 diabetic models. Peptide-driven supramolecular systems, including GLP-1 nanofibre hydrogels, provided sustained glycaemic control lasting weeks to over 40 days in preclinical models. Furthermore, emerging glucose-responsive platforms, such as glucose oxidase-integrated hydrogels and ROS-responsive polymersomes, enabled closed-loop insulin release, with polymersomes releasing >90% insulin under hyperglycaemic conditions. Several nanoarchitectures also supported cell-based therapies, combining stem-cell-derived islet cells with peptide-loaded nanomatrices to restore glycaemic regulation.
Key Findings
- Hydrophobic ion-paired exenatide lipid nanocarriers achieved 16.3-27.9% oral bioavailability.
- Charge-switchable PCB122/INS nanoparticles enabled oral insulin bioavailability of ~27% with sustained glucose lowering.
- Polymeric D-PLA-PEG stereocomplex nanoassemblies provided ultra-long insulin release for up to 16 weeks subcutaneously.
- GLP-1 nanofibre hydrogels sustained glycaemic control for over 40 days in preclinical models.
- Glucose-responsive polymersomes released >90% insulin under hyperglycaemic conditions, enabling closed-loop delivery.
Why It Matters
These bioinspired nanoarchitectures represent a paradigm shift in peptide delivery for diabetes management, potentially transforming patient experience by reducing injection frequency and enabling oral administration. For peptide users and clinicians, this could mean less invasive, more convenient, and more consistent therapeutic regimens. The demonstrated ultra-long release profiles (e.g., 16 weeks for insulin) could significantly improve adherence and glycaemic stability, moving towards "set-and-forget" protocols. Oral bioavailability improvements (up to 27.9%) open doors for non-injectable GLP-1 and insulin therapies. While still largely preclinical, these advancements lay the groundwork for future clinical trials, potentially leading to novel drug formulations that enhance the efficacy and safety of existing antidiabetic peptides.